Arvey Stone, MD
Pulmonary Disease · Park Ridge, ILNPI 1114998713
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 260 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,423 and has fallen 63.4% since, to $520 in 2024.
Across 260 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$786
- Boehringer Ingelheim$589
- Electromed, Inc.$575
- Vertex$379
- Sanofi$373
- plus $2K from 23 others
Across 26 payments — averaging $5468.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$134K
- AbbVie$7K
- Vivus LLC$2K
What the payments were for
- Food & beverage$5,23897%
- Education$1703%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $1,041 |
| GSK | 59 | $786 |
| Boehringer Ingelheim | 33 | $589 |
| Electromed, Inc. | 33 | $575 |
| Vertex | 14 | $379 |
| Sanofi | 13 | $373 |
| Genentech USA, Inc. | 15 | $303 |
| Regeneron Healthcare Solutions, Inc. | 10 | $239 |
| Nestle Healthcare Nutrition Inc. | 7 | $147 |
| Chiesi USA, Inc. | 1 | $128 |
| Actelion Pharmaceuticals US, Inc. | 4 | $92 |
| Mylan Specialty L.p. | 4 | $89 |
| Melinta Therapeutics, LLC | 5 | $80 |
| Watermark Medical, Inc. | 1 | $79 |
| Insmed, Inc. | 4 | $73 |
| Philips North America LLC | 2 | $55 |
| Novartis | 3 | $55 |
| La Jolla Pharmaceutical Company | 1 | $49 |
| Baxter Healthcare | 2 | $44 |
| Gilead | 2 | $41 |
| CSL Behring | 2 | $34 |
| AbbVie | 2 | $32 |
| Advanced Respiratory, Inc | 1 | $29 |
| Nabriva Therapeutics, PLC | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Amgen | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Merck | 1 | $14 |
| United Therapeutics Corporation | 3 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,408 in reported general payments places this provider in the 70th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 62 | $1,667,360 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 200 | $206,982 |
| OfevNintedanib Esylate | 15 | $190,765 |
| Dupixent PenDupilumab | 23 | $108,829 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 86 | $51,973 |
| Breo ElliptaFluticasone/Vilanterol | 56 | $34,806 |
| Arnuity ElliptaFluticasone Furoate | 32 | $11,676 |
| Spiriva RespimatTiotropium Bromide | 15 | $8,386 |
| Spiriva HandihalerTiotropium Bromide | 11 | $7,816 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 42 | $6,905 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $6,593 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 134 | $3,655 |
| Ventolin HfaAlbuterol Sulfate | 35 | $2,203 |
| Azithromycin | 57 | $636 |
| Montelukast Sodium | 40 | $385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta | $379 | $1,667,36062 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $786 | $305,437374 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $589 | $199,15130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Park Ridge
- Abdul Hamid AlraiyesPark Ridge$76K
- Douglas HogarthChicago$2.9M
- Steven WhiteChicago$970K
- Momen WahidiChicago$779K
- Septimiu MurguChicago$633K
- Ayodeji AdegunsoyeChicago$561K
- Kristopher McDonoughJoliet$461K
- Ravi KalhanChicago$375K
- Brian GaribaldiChicago$356K
- Danish ThameemChampaign$353K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.